# Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes

> **NCT05040971** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 207 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Semaglutide 2.4 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05040971
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-06
- **Primary completion:** 2023-01-06
- **Final completion:** 2023-07-14
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040971, "Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05040971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*